How do we value a cure?

被引:13
|
作者
Husereau, Don [1 ]
机构
[1] Inst Hlth Econ, Ottawa, ON, Canada
关键词
consumer behavior; economics; diffusion of innovation; financial; health; insurance; patient preference; reimbursement; reimbursement mechanisms; risk sharing; HEALTH-CARE; INNOVATIVE TECHNOLOGIES; DECISION-ANALYSIS; TASK-FORCE; PREFERENCES; PREVENTION; DESIGN; RISK;
D O I
10.1586/14737167.2015.1039519
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Future perceptions of the value of curative therapies will likely reflect debates happening today about preferences for funding of preventive versus treatment programs, as well as funding orphan drugs. Little is known about how society will value curative therapies versus standard treatments, and the significant role of a host of psychological factors compared to overarching concerns about opportunity costs will likely lead to significant tension between payers and the public. More research to clarify societal preferences and healthcare goals in regards to curative therapies and in light of the potential for significant opportunity costs will be required. Given what we know about preferences for the funding of prevention and treatment measures, we should expect that cures will not be held to a different measure.
引用
收藏
页码:551 / 555
页数:5
相关论文
共 50 条
  • [1] How Do We Define Cure of Diabetes?
    Buse, John B.
    Caprio, Sonia
    Cefalu, William T.
    Ceriello, Antonio
    Del Prato, Stefano
    Inzucchi, Silvio E.
    McLaughlin, Sue
    Phillips, Gordon L., II
    Robertson, R. Paul
    Rubino, Francesco
    Kahn, Richard
    Kirkman, M. Sue
    [J]. DIABETES CARE, 2009, 32 (11) : 2133 - 2135
  • [2] What is a cure and how do we get there?
    Skinner, MW
    Lillicrap, DP
    Mcmillan, J
    Ozelo, MC
    Pierce, GF
    [J]. HAEMOPHILIA, 2004, 10 : 115 - 118
  • [3] How do we value people?
    Wujek, JH
    [J]. IEEE TECHNOLOGY AND SOCIETY MAGAZINE, 1997, 16 (03) : 4 - 4
  • [4] How do we determine value?
    Brooks, Leslie Sadeghi
    [J]. JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2018, 252 (08): : 927 - 927
  • [5] DO WE CURE PATIENTS WITH ALLO-HCT? HOW DO WE PREVENT RELAPSE?
    Platzbecker, U.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S3 - S3
  • [6] Onychomycosis: What do we consider/how do we define cure and what are the barriers to achieving it?
    Gupta, Aditya
    Simpson, Fiona
    Nakrieko, Kerry-Ann
    Paquet, Maryse
    Brintnell, William
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB11 - AB11
  • [7] Health Care Costs: How Do We Decide Value? When Do We Decide? How Do We Particularize the Decisions?
    Theriault, Richard L.
    [J]. ONCOLOGIST, 2012, 17 (02): : 157 - 159
  • [8] How do we ensure successful cure of nervous diseases in institutions ?
    Laehi, M
    [J]. ARCHIV FUR PSYCHIATRIE UND NERVENKRANKHEITEN, 1905, 40 (01): : 212 - 223
  • [9] Hooray for Chaplains! How Do We Prove Their Value?
    Matlock, Daniel D.
    [J]. JOURNAL OF PALLIATIVE MEDICINE, 2017, 20 (05) : 442 - 443
  • [10] How Do We Know the Value of Our Research?
    Krumholz, Harlan M.
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2013, 6 (04): : 371 - 372